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Abstract
Background: The aim of the study was to assess the morbidity and efficacy of repeat cryoablation (CA) in the
treatment of localized prostate cancer.
Methods: Twenty-seven patients with median age of 71 years (range 48–80) who underwent repeat CA between
April 2003 and April 2011 at a single institution were included. The median initial prostate-specific antigens (PSA)
and Gleason values were 6.2 ng/ml (range 4–23.6) and 7 (range 6–9), respectively. Twenty-four patients underwent
two CA treatments, and three patients underwent three CA treatments. Pre- and perioperative parameters and
oncological and functional outcomes were evaluated.
Results: No intraoperative complications occurred. After the first CA, PSA was undetectable in 10 patients, and the
median nadir PSA value was 0.65 ng/ml (range 0.1–4.9). After the second CA, 4 patients had undetectable PSA, and
the median nadir PSA value was 1.25 ng/ml (range 0.2–7.9). For patients who underwent a third CA treatment, no
patients had undetectable PSA, and the subsequent median nadir PSA value was 1.6 ng/ml (range 0.4–4.5). Two
patients had incontinence (1 pad per day) following repeat CA. One patient had urinary retention after the third CA
treatment, and one had urethral stricture. The mean hospitalization and follow-up periods were 1 day (range 0–2)
and 51.5 months (range 11–96), respectively.
Conclusions: Repeat CA successfully reduced PSA levels, and complications were modest. We conclude that repeat
CA is a feasible, safe, and effective treatment option for localized prostate cancer.
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Background
With the introduction of prostate-specific antigen (PSA)
screening, an increasing number of men are being diag-
nosed with low-grade, low-stage, and small-volume can-
cers that are potentially biologically indolent. Choosing
whether and how to treat such tumors remains challen-
ging. Men newly diagnosed with low-risk prostate cancer
are frequently treated with standard therapies, i.e., rad-
ical prostatectomy (RP), external beam radiation therapy,
brachytherapy, androgen deprivation therapy, or conser-
vative management [1]. These therapies are associated
with high overall cancer-specific and biochemical
recurrence-free survival; however, RP, radiation therapy,
and androgen deprivation therapy are accompanied by
side effects that may negatively affect patients’ health-
related quality of life. Conservative management was
reported to induce anxiety and elevate stress: however,
active surveillance for low-risk prostate cancer was
strongly supported by Klotz et al. in many recent studies
[2, 3]. As such, renewed interest has emerged in using
minimally invasive approaches such as CA to treat clin-
ically localized prostate cancer.
Cryotherapy has become more widespread in prac-
tice because of a better understanding of cryobiology
[4], introduction of third-generation cryoprobes, and
improvement in biopsy and imaging techniques that
have enhanced the ability to map the foci and
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locations of tumors within the prostate, subsequently
reducing morbidity while improving effectiveness [4–6].
Information is lacking on whether CA is effective in
the repeat setting when disease recurs after initial
CA, and there is no formal definition of CA eligible
tumor. Moreover, morbidity associated with CA has
been primarily reported from single hospital-based
studies, typically in highly selected patients [7–13].
Herein, we are the first to report on the morbidity
and efficacy of repeat CA as a primary and salvage
option for the treatment of clinically localized pros-
tate cancer.
Methods
We retrospectively evaluated the hospital records of pa-
tients who underwent a repeat CA procedure at a single
institution between April 2003 and April 2011. Twenty-
seven patients with median age 71 years (range 48–80)
underwent repeat CA for biopsy-proven prostate can-
cer. Repeat cryotherapy procedures were performed
with similar methodology to the initial salvage cryo-
therapy procedure which has been described in detail
elsewhere. [14]. All procedures were performed under
general anesthesia with the urethral warming catheter
in place and set at a temperature of 42 °C to protect
the urethra. Whole-gland CA was applied except in five
patients where focal therapy was used. The median
PSA value and Gleason score at initial diagnosis were
6.2 ng/ml (range 4–23.6) and 7 (range 6–9), respect-
ively. The clinical stages were T1c in 15 patients, T2 in
11 patients, and T3 in 1 patient. The preoperative
demographic characteristics and functional and onco-
logical outcomes were summarized in Table 1. All
patients had negative bone scan and computed tomog-
raphy findings prior to application of CA. Staging
transrectal ultrasonography was performed to rule out
seminal vesicle involvement. Biopsy of the seminal vesi-
cles is obtained at the time of transrectal ultrasound-
guided prostate biopsies. After the prostate biopsies are
obtained, the seminal vesicle tissue is visualized ultraso-
nographically, and two cores are obtained of each sem-
inal vesicle. Fifteen patients (56 %) had undergone CA
as primary therapy; however, 12 patients (44 %) had
had hormone therapy (HT) and/or radiation therapy
prior to first CA (Table 1). Neoadjuvant HT in 10 pa-
tients over a median period of 7 months (range 3–96).
Twenty-four patients underwent two cryosurgical abla-
tion procedures, and three patients had three proce-
dures. One patient had the second CA for the right
seminal vesicle involvement only, and one patient had
open pelvic lymph nodes dissection (PLND) in con-
junction with CA. Additional therapy was given for 13
patients: 8 received HT, 3 received HT and/or radiation
therapy, 1 received radiation therapy, chemotherapy,
and ketoconazole, and 1 patient underwent robotic RP.
Ethical approval from MD Anderson Cancer Center
was obtained, and the study was carried out in compli-
ance with the Helsinki Declaration. The patients were
informed about the operation and consent was ob-
tained. Biochemical recurrence after CA was defined as
detectable measurement of PSA. Continence was de-
fined as use of no pads or a small liner for security pur-
poses only. Potency was defined as the ability to
achieve an erection adequate for penetration with or
without medication (i.e., phosphodiesterase-5 inhibi-
tors, intracavernous injection, or vacuum). The median
hospitalization and follow-up periods were 1 day (range
0–2) and 40.5 months (range 11–96).
Table 1 Demographic characteristics and oncological and
functional outcomes of the study group
Variable Value
Patients (n) 27
Age (years, median, range) 71 (48–80)
Initial PSA value (ng/ml, median, range) 6.2 (4–23.6)
Initial volume of prostate before CA (cc, median, range) 29 (15–53)
Volume of prostate after repeat CA (cc, median, range) 18 (10–48)
Gleason score at initial diagnosis
6 (n %) 5 (19)
7 (n %) 13 (48)
8 or 9 (n %) 9 (33)
Initial clinical stage before first CA
T1c (n %) 15 (55)
T2 (n %) 11 (41)
T3 (n %) 1 (4)
Initial therapy before first CA
HT (n %) 6 (22)
HT and either RT or BT (n %) 5 (19)
RT (n %) 1 (4)
Interval between first CA and positive biopsy
(median, months)
23 (6–63)
PSA value at positive biopsy after first CA (median, ng/ml) 2.7 (0.2–7.8)
Postoperative complications of repeat CA (n %)
Continence (no pad usage) 24/26 (92)
Stricture 1/26 (3.84)
PSA value at last follow-upa
Median value among patients with detectable PSA
(ng/ml)
0.8 (0.2–50)
Patients with undetectable PSA (n %) 5/26a (19)
Patients with PSA value <0.5 ng/ml (n %) 13/26 (50)
Patients with PSA value ≥0.5 ng/ml (n %) 8/26 (31 %)
n number of patients, CA cryoablation, PSA prostate-specific antigen,
HT hormonal therapy, RT radiation therapy, BT brachytherapy
aOne patient did not return for follow-up after the second CA
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Results
The procedure was well tolerated in all patients, and no
intraoperative complications occurred. The PSA value
before the first CA procedure was 5.6 ng/ml (range 0–
15). Ten patients (37 %) had undetectable PSA after the
first CA. Clinical variables assessed before and after each
CA procedure are summarized in Table 2. One patient
did not return for follow-up after the second CA. The
median nadir PSA values after the first, second, and
third CA were 0.65, 1.25, and 1.6 ng/ml, respectively.
The median interval from first CA to first positive bi-
opsy was 23 months (range 6–63), with median value of
PSA 2.7 ng/ml (range 0.2–7.9). The median period be-
tween the first CA and the second CA was 27 months
(range 7–78). The positive biopsy cores were located at
the apex and/or base of the prostate in 65 % of patients
undergoing the first CA, 70 % of patients undergoing
the second CA, and 100 % of patients undergoing a third
CA. Only one patient had failure of HT and chemother-
apies and developed bone metastasis 14 months after
the first CA. Five patients (5/26, 19 %) (two of them
without additional therapy) had undetectable PSA level
at the last follow-up, and 8 patients (8/26, 31 %) had de-
tectable PSA values less than 0.5 ng/ml. Twenty patients
(20/26.77 %) had PSA values less than 2 ng/ml at the last
follow-up, and the median PSA value was 0.8 ng/ml
(range 0.2–50) in all patients with detectable PSA.
According to Clavien classification system, postopera-
tive complications were seen in five patients (5/26,
19 %); three patients had grade I, one patient had grade
II, and one patient had grade IIIb. One patient (4 %) de-
veloped a severe lower urinary tract symptom of acute
retention, which started as irritative symptoms after the
first CA and increased after the second and third CA;
injury of the prostatic urethra was observed after the
third CA. One patient (4 %) had urethral stricture with
overactive bladder symptoms, and a transurethral blad-
der neck resection was performed. Three patients (11 %)
developed mild perioperative complications—mild lower
urinary tract symptoms, scrotal edema, and perineal ab-
scess which resolved spontaneously. One patient devel-
oped neuropathy in the lower extremity and spinal
stenosis due to radiation therapy that was given after the
third CA. Two patients (8 %) had incontinence with the
need for one pad per day (Table 1). Those two patients
were primary cases without history of radiotherapy
before CA. One of them had history of urethral stricture
and underwent transurethral resection. Regarding erect-
ile dysfunction, only 6 patients were potent before CA,
and 21 patients either had no available data about erect-
ile dysfunction or could not receive medication for it
due to older age or comorbid diseases. However, 5
patients (19 %) could achieve erection with medication
(3 with intracavernous injection, 1 with phosphodiesterase-
5 (PDE-5) inhibitors, and 1 with a vacuum device) at the
end of the second CA.
Discussion
Albeit selection criteria for men undergoing prostate CA
have yet to be definitely established, optimal candidates
for this procedure generally include those with lower-
stage, lower-volume disease, and PSA values less than
20 ng/ml [15]. Our findings demonstrate the validity of
CA as an effective and safe treatment option not only
for lower-risk patients but also for the intermediate- or
even high-risk patients with localized prostate cancer.
Similarly, Roberts et al. reported, in an analysis of a
Medicare-linked database from 2004 to 2005, that
16.1 % of those who underwent CA therapy had high-
risk disease [16]. In our series, only 5 patients (19 %)
Table 2 Pre- and postoperative clinical variables by cryoablation procedure
Variable First CA Second CA Third CA
Patients (n) 27 27 3
Median PSA before CA (ng/ml, range) 5.6 (0–15) 3 (0–6.94) 2 (1.1–12.8)
Median total cores at biopsy before CA (n, range) 10 (4–14) 12 (6–92) 13 (12–60)
Median positive cores at biopsy before CA (n, range) 3 (1–12) 2 (1–9) 4 (1–7)
Median percentage of positive cores before CA (%, range) 33 (8–100) 10 (1–75) 8 (5–58)
Median cumulative length of cancer at biopsy before CA (mm) 16 (1–136) 4.5 (1–53.5) 17 (1–31)
Location of cancer at apex and/or base (n %) 15/23 (65) 19/27 (70) 3/3 (100)
Location of cancer at apex (n %) 6/23 (26) 12/27 (44) 1/3 (33)
Location of cancer at base (n %) 3/23 (13) 4/27 (15) 1/3 (33)
Undetectable PSA after CA (n %) 10/27 (37.03) 4/27 (14.81) 0
Nadir PSA after CA (ng/ml, range) 0.65 (0.1–4.9) 1.25 (0.2–7.9) 1.6 (0.4–4.5)
Duration of CA procedure (minutes) 115 (186–169) 100 (59–168) 130 (109–250)a
n number, CA cryoablation, PSA prostate-specific antigen
aOne patient underwent open PLND with third CA
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had a Gleason score <6 and 9 patients (33 %) had a
Gleason score of either 8 or 9. The clinical stages for 5
patients (4 patients T2b, 1 patient T3) were also not
confined to a low-risk group. One patient developed
bone metastasis, 19 % of the patients had undetectable
PSA level, and 50 % had a PSA level less than 0.5 ng/ml
after CA. The patient who developed bone metastasis
had a clinical stage of T2a, 100 % of cores positive, and a
high volume (136 mm) of cancer at biopsy with a Gleason
score of 8 and 5 years of neoadjuvant hormone therapy;
thus, this patient had a poor prognosis and benefit from
other kinds of therapies was unlikely. Three patients had
progressive disease from T1c to T3 (seminal vesicle in-
volvement) after CA; 1 patient underwent a second CA
for the right seminal vesicles, and his last PSA test yielded
an undetectable level, and the other patient, who had a
history of radiation therapy before CA, underwent robotic
RP without complication and at his last follow-up was
under watchful waiting with a PSA level of 0.4 ng/ml. One
patient had a positive lymph node after the second CA
and underwent open pelvic lymph node dissection. A
biopsy after the last CA detected no cancer, and his PSA
value at last follow-up <0.1 ng/ml. An advantage of CA
for intermediate- or even high-risk patients with localized
prostate cancer is that it does not hinder patients from
undergoing other kinds of salvage therapies such as ro-
botic RP; Pisters et al. reported on the feasibility of RP
after neoadjuvant CA [17].
Cryotherapy can be used as a salvage treatment, and it
is currently the only repeatable therapy for localized
prostate cancer. Among salvage therapies, salvage RP
and salvage CA represent the most feasible and effective
therapeutic options for prostate cancer that recurs after
radiation therapy. Salvage cryotherapy is performed four
times as often as salvage RP, although both procedures
remain underutilized for the management of recurrent
prostate cancer [18, 19]. Pisters et al. performed a strati-
fied control comparison of biochemical disease-free
survival after salvage RP and salvage CA [20]. Compared
to salvage CA, salvage RP resulted in superior biochem-
ical disease-free survival, 21 % for salvage CA vs 61 %
for salvage RP at 5 years [20]. Thus, salvage CA is best
considered in older patients who decline to undergo
salvage RP. However, there is no curative therapy in
prostate cancer that is not responding to radiotherapy,
and there is no definition of success for CA. The PSA
level before salvage CA and Gleason score correlated
with biochemical progression-free survival (bPFS): the
initial PSA level of <0.6 ng/mL after salvage CA por-
tends a favorable (67 % at 36 months) bPFS [21]. In our
series, CA was used as salvage therapy for 12 patients
(44 %, 6 of whom had previous radiation therapy (RT))
and as primary therapy for 15 patients. Although the
previously reported intraoperative and postoperative
complication rates have been high after salvage CA, our
patients had no rectal injury, bowel bleeding, or hydro-
nephrosis. Therefore, CA is not associated with the high
intraoperative complication rate of other kinds of salvage
therapies, and it is a feasible treatment modality in
patients for whom initial therapies, including radiation
and CA, have failed. Many recent studies have reported
on the validity of salvage CA ablation after radiation
therapy for prostate cancer [22]; however, we found only
one study about the feasibility of repeat CA after the
failure of the primary CA [23]. In one of these studies,
de Castro and his colleagues compared salvage focal
with standard salvage total CA for locally recurrent
prostate cancer after primary radiation therapy [22].
They concluded that salvage focal and salvage total CA
are feasible and safe with acceptable mid-term oncological
outcomes and that morbidity was lower for salvage focal
CA than for salvage total CA [22]. Focal therapy is a
modification of the standard CA technique aiming to only
treat the portion of the prostate gland which has the can-
cer with minimization of complications especially potency.
This kind of therapy was introduced by Onik et al. [24] in
2004 and supported by many recent studies regarding its
efficacy in the treatment of primary and radiorecurrent
locally prostate cancer [25].
The postoperative complications occurring after CA
have been widely studied in small single hospital-based
studies. Urinary incontinence ranged from 1.3 to 9.5 %
[9–11, 13, 26], urinary strictures from 1.7 to 17 % [10, 13],
lower urinary tract obstruction and retention from 6.6
to 13 % [25], erectile dysfunction from 47 to 94.9 %
[10, 11, 13], and fistula less than 1 % [10–13]. In our
cohort of men receiving repeat CA, the majority of
the postoperative complications were clinically insignifi-
cant. According to Clavien classification system, only one
patient had grade IIIB complication and endoscopic man-
agement was done. No urinary or bowel fistula was ob-
served. Incontinence occurred in two patients (8 %), with
only one pad per day. One of them had had rectal abscess
surgery 24 years before CA, and he suffered from mild
nocturia after the first CA, which increased after the sec-
ond CA. The second patient had urethral stricture with
overactive bladder symptoms after the second CA; thus,
bladder neck transurethral resection was done 32 months
after the second CA. This patient had lower urinary tract
symptoms before the first CA and had a history of ureth-
ral stricture after a fall from a tree; several urethral
dilations had been done before the first CA. Thus, postop-
erative complications occurring after CA were not only
attributable to the CA but also to the previous history.
Another complication seen (one patient) was severe lower
urinary tract symptoms and urinary retention after the
third CA, due to injury of the prostatic urethra; thus, a
Foley catheter was placed. This patient also had a history
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of irritative symptoms, which increased after the first CA
and became severe after the third CA. Erectile dysfunction
is a well-known side effect of CA; in our study, although
the patients were older and the majority of the patients
either were not potent before CA or were not interested
in sex therapy, five patients could achieve erection with
the help of medication after the last CA. The evaluation of
erectile dysfunction in our study was suboptimal; there-
fore, it is difficult to make a definitive comment regarding
potency. However, 19 % of the patients after repeat CA
could achieve erections sufficient for penetration, which is
a promising finding.
Location of cancer in the prostate base and/or apex is
one of the greatest challenges for application of CA. The
use of thermocouples in the apex and base to document
adequate freezing temperatures could improve the re-
sults of salvage cryotherapy. In particular, the apex is
sometimes difficult to visualize ultrasonographically and
a thermocouple in both the right and left apical tissue
may improve the effectiveness of salvage cryotherapy. In
our study, the proportions of patients with cancer sited
at the base and/or apex before the first, second, and
third treatments were 65, 70, and 100 %, respectively
(Table 2). Two patients who achieved undetectable PSA
levels after the last CA had such cancers (one patient,
cancer at the apex; and one patient, cancer at the base
and apex). An undetectable PSA level is unlikely to be
achieved after CA because a rim of PSA-producing peri-
urethral tissue will invariably remain. Biopsy is the most
definitive determination of failure or success; however,
there is no consensus on when and at which PSA level
should be performed.
Conclusions
Our study demonstrates that repeat CA is both safe and
effective. Cryotherapy as a primary or salvage option can
be repeated with a modest complication rate and reason-
able efficacy. Low- and high-risk localized prostate cancer
can be treated with CA without hindering the patients
from undergoing other kinds of salvage therapies. Base or/
and apex of the prostate are the most common place for
the recurrence after CA.
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